Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2025)
Ultragenyx Pharmaceutical (RARE) reported Gains from Investment Securities of -$693000.0 for Q4 2025, up 42.35% year-over-year from -$486841.6 in Q4 2024, and down 143.18% on a QoQ basis from $1.6 million in Q3 2025.
Ultragenyx Pharmaceutical (RARE) has 13 years of Gains from Investment Securities data on file, last reported at -$693000.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 42.35% year-over-year to -$693000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 6.95% YoY) and the FY2025 annual result came in at $2.0 million, changed 0.0% from the prior year.
- Gains from Investment Securities retreated to -$693000.0 in Q4 2025 per RARE's latest filing, from $1.6 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.5 million in Q2 2023 and bottomed at -$1.8 million in Q3 2023.
- The 5-year median for Gains from Investment Securities is $39000.0 (2022), against an average of $558600.0.
- Peak annual rise in Gains from Investment Securities reached 34480.0% in 2023, while the deepest fall reached 434.29% in 2023.
- Tracing RARE's Gains from Investment Securities over 5 years: stood at $455000.0 in 2021, then tumbled by 102.2% to -$10000.0 in 2022, then jumped by 34480.0% to $3.4 million in 2023, then tumbled by 134.96% to -$1.2 million in 2024, then jumped by 42.35% to -$693000.0 in 2025.
- Per Business Quant, the three latest RARE Gains from Investment Securities figures stand at -$693000.0 (Q4 2025), $1.6 million (Q3 2025), and $88000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -693,000.00 |
| Dec 31, 2025 | -693,000.00 |
| Sep 30, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | -1.20 Mn |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | -1.79 Mn |
| Sep 30, 2023 | -1.79 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | -187,000.00 |
| Mar 31, 2023 | -187,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Sep 30, 2022 | -1.59 Mn |
| Sep 30, 2022 | -1.59 Mn |
| Jun 30, 2022 | 1.86 Mn |
| Jun 30, 2022 | 1.86 Mn |
| Mar 31, 2022 | -35,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Dec 31, 2021 | 455,000.00 |
| Dec 31, 2021 | 455,000.00 |
| Sep 30, 2021 | 998,000.00 |
| Sep 30, 2021 | 998,000.00 |
| Jun 30, 2021 | -186,000.00 |
| Jun 30, 2021 | -186,000.00 |
| Mar 31, 2021 | -325,000.00 |
| Mar 31, 2021 | -325,000.00 |
| Dec 31, 2020 | -2.85 Mn |
| Dec 31, 2020 | -2.85 Mn |
| Sep 30, 2020 | 4.14 Mn |
| Sep 30, 2020 | 4.14 Mn |
| Jun 30, 2020 | 477,000.00 |
| Jun 30, 2020 | 477,000.00 |
| Mar 31, 2020 | -463,000.00 |
| Mar 31, 2020 | -463,000.00 |
| Dec 31, 2019 | -16.96 Mn |
| Dec 31, 2019 | -16.96 Mn |
| Sep 30, 2019 | 15.35 Mn |
| Sep 30, 2019 | 15.35 Mn |
| Jun 30, 2019 | -9.29 Mn |
| Jun 30, 2019 | -9.29 Mn |
| Mar 31, 2019 | 8.28 Mn |
| Mar 31, 2019 | 8.28 Mn |
| Dec 31, 2018 | 11,000.00 |
| Dec 31, 2018 | 11,000.00 |
| Jun 30, 2018 | 2.25 Mn |
| Jun 30, 2018 | 2.25 Mn |
| Mar 31, 2018 | 1.83 Mn |
| Mar 31, 2018 | 1.83 Mn |
| Dec 31, 2017 | -30,000.00 |
| Dec 31, 2017 | -30,000.00 |
| Sep 30, 2017 | 1.88 Mn |
| Sep 30, 2017 | 1.88 Mn |
| Jun 30, 2017 | 1.82 Mn |
| Jun 30, 2017 | 1.82 Mn |
| Mar 31, 2017 | -75,000.00 |
| Mar 31, 2017 | -75,000.00 |
| Dec 31, 2016 | -1.97 Mn |
| Dec 31, 2016 | -1.97 Mn |
| Sep 30, 2016 | 1.38 Mn |
| Sep 30, 2016 | 1.38 Mn |
| Jun 30, 2016 | 1.05 Mn |
| Jun 30, 2016 | 1.05 Mn |
| Mar 31, 2016 | 1.47 Mn |
| Mar 31, 2016 | 1.47 Mn |
| Dec 31, 2015 | -139,000.00 |
| Dec 31, 2015 | -139,000.00 |
| Sep 30, 2015 | 1.04 Mn |
| Sep 30, 2015 | 1.04 Mn |
| Jun 30, 2015 | 950,295.00 |
| Jun 30, 2015 | 950,295.00 |
| Mar 31, 2015 | 7,000.00 |
| Mar 31, 2015 | 7,000.00 |
| Dec 31, 2014 | -51,000.00 |
| Dec 31, 2014 | -51,000.00 |
| Mar 31, 2014 | 3.32 Mn |
| Mar 31, 2014 | 3.32 Mn |
| Dec 31, 2013 | 1.11 Mn |
| Dec 31, 2013 | 1.11 Mn |
| Sep 30, 2013 | 706,000.00 |
| Sep 30, 2013 | 706,000.00 |
| Jun 30, 2013 | 374,000.00 |
| Jun 30, 2013 | 374,000.00 |
| Mar 31, 2013 | -2,000.00 |
| Mar 31, 2013 | -2,000.00 |